Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4

Chemical Biology and Drug Design

Volumn 67, Issue 1, 2006, Pages 13-26

  Kazmierski, Wieslaw M ^a   Kenakin, Terry P ^a   Gudmundsson, Kristjan S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 3 O (3,3 DIMETHYLSUCCINYL)BETULIC ACID; 4 (8 BETULINOYLAMINOOCTANOYLAMINO) 3 HYDROXY 6 METHYLHEPTANOIC ACID; ADS J1; ADS J2; ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; ANTIVIRUS AGENT; APLAVIROC; BETULIC ACID; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLO(NAPHTHYLALANYLGLYCYLDEXTROTYROSYLARGINYLARGININE); ENFUVIRTIDE; FORMAZAN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; KRH 1636; KRH 2731; KY 001; KY 002; MARAVIROC; NB 2; NB 64; PEPTIDE; RANTES; T 140; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; BINDING AFFINITY; CHEMICAL STRUCTURE; CLINICAL TRIAL; CYTOTOXICITY; DNA REPLICATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS; VIRUS ADSORPTION; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; DRUG DESIGN; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745092046     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2005.00319.x     Document Type: Review

References (127)

1. Doms R.W. ( 2000) Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276 : 229 237.
2. Carr C.M. Kim P.S. ( 1993) A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell (Cambridge, MA, United States) 73 : 823 832.
3. Liu S. Lu H. Niu J. Xu Y. Wu S. Jiang S. ( 2005) Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120. J Biol Chem 280 : 11259 11273.
4. Wild C. Oas T. McDanal C. Bolognesi D. Matthews T. ( 1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89 : 10537 10541.
5. Kazmierski W.M. McDermed J. ( 1995) Disruption of helix-helix interactions in biologically relevant proteins: HIV-1 inhibition by gp41 fragments. In: Maia Hernani L.S., editor. Peptides 1994, Proceedings of the European Peptide Symposium, 23rd, Braga, Port., Sept. 4-10, 1994 p. 52 53
6. Kazmierski W.M. McDermed J. Aulabaugh A. ( 1996) A new experimental method to determine the mutual orientation of helixes in coiled-coil proteins: structural information about the dimeric interface of cJun, cFos, GCN4, and gp41. Chemistry-A European Journal 2 : 403 411
7. Kazmierski W.M. McDermed J. ( 1994) A new method for defining dimerization interfaces in proteins. In: Hodges Robert S. Smith John A., editors. Pept: Chem, Struct Biol, Proc Am Pept Symp, 13th, ESCOM, Leiden, Neth.,p. 1045 1047
8. Kazmierski W.M. Hazen R.J. Aulabaugh A. StClair M.H. ( 1996) Inhibitors human immunodeficiency virus type 1 derived from gp41 transmembrane protein: structure-activity studies. J Med Chem 39 : 2681 2689
9. O'Shea E.K. Rutkowski R. Stafford W.F. III. Kim P.S. ( 1989) Preferential heterodimer formation by isolated leucine zippers from fos and jun. Science 245 : 646 648.
10. O'Shea E.K. Rutkowski R. Kim P.S. ( 1989) Evidence that the leucine zipper is a coiled coil. Science 243 : 538 542.
11. O'Shea E.K. Rutkowski R. Kim P.S. ( 1992) Mechanism of specificity in the Fos-Jun oncoprotein heterodimer. Cell (Cambridge, MA, United States) 68 : 699 708.
12. Glover J.N.M. Harrison S.C. ( 1995) Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA. Nature (London) 373 : 257 261.
13. Harbury P.B. Zhang T. Kim P.S. Alber T. ( 1993) A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science (Washington, DC, United States) 262 : 1401 1407.
14. Dwyer J.J. Hasan A. Wilson K.L. White J.M. Matthews T.J. Delmedico M.K. ( 2003) The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 42 : 4945 4953.
15. Ji H. Shu W. Burling F.T. Jiang S. Lu M. ( 1999) Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol 73 : 8578 8586.
16. Chan D.C. Chutkowski C.T. Kim P.S. ( 1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 95 : 15613 15617.
17. Kazmierski W.M. McDermed J. ( 1995) Synthesis of the carbonic acid benzotriazol-1-yl-ester-(2-biotinylamino)-9H-fluoren-9-ylmethyl ester: a convenient transient-biotinylation reagent for use in affinity chromatography. Tetrahedron Lett 36 : 9097 9100.
18. Kazmierski W.M. Hurley K. ( 1996) New reagent for the affinity purification of peptides. In: Kauyama Pravin T.P. Hodges Robert S., editors. Peptides: Chemistry, Structure and Biology, Proceedings of the American Peptide Symposium, 14th, Columbus, Ohio, June 18-23, 1995 Mayflower Scientific, Kingswinford, UK, p. 63 64.
19. Greenberg M. q5 Cammack N. Salgo M. Smiley L. ( 2004) HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 14 : 321 337.
20. Chan D.C. Fass D. Berger J.M. Kim P.S. ( 1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell (Cambridge, Massachusetts) 89 : 263 273.
21. Weissenhorn W. q6 Wharton S.A. Calder L.J. Earl P.L. Moss B. Aliprandis E. Skehel J.J. Wiley D.C. ( 1996) The ectodomain of HIV-1 env subunit gp41 forms a soluble, α-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J 15 : 1507 1514.
22. Debnath A.K. Radigan L. Jiang S. ( 1999) Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem 42 : 3203 3209.
23. Zhao Q. Ernst J.T. Hamilton A.D. Debnath A.K. Jiang S. ( 2002) XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res Hum Retroviruses 18 : 989 997.
24. Jiang S. Lu H. Liu S. Zhao Q. He Y. Debnath A.K. ( 2004) N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother 48 : 4349 4359.
25. Jin B.-S. Lee W.-K. Ahn K. Lee M.K. Yu Y.G. ( 2005) High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41. J Biomol Screen 10 : 13 19.
26. Mayaux J.F. Bousseau A. Pauwels R. Huet T. Henin Y. Dereu N. Evers M. Soler F. Poujade C. De Clercq E. ( 1994) Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci U S A 91 : 3564 3568.
27. Labrosse B. Pleskoff O. Sol N. Jones C. Henin Y. Alizon M. ( 1997) Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J Virol 71 : 8230 8236.
28. Fujioka T. Kashiwada Y. Kilkuskie R.E. Cosentino L.M. Ballas L.M. Jiang J.B. Janzen W.P. Chen I.S. Lee K.H. ( 1994) Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 57 : 243 247.
29. Kashiwada Y. Hashimoto F. Cosentino L.M. Chen C.H. Garrett P.E. Lee K.H. ( 1996) Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 39 : 1016 1017.
30. Li F. Goila-Gaur R. Salzwedel K. Kilgore N.R. Reddick M. Matallana C. Castillo A. Zoumplis D. Martin D.E. Orenstein J.M. Allaway G.P. Freed E.O. Wild C.T. ( 2003) PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 100 : 13555 13560.
31. Kazmierski W.M. Boone L. Lawrence W. Watson C. Kenakin T. ( 2002) CCR5 Chemokine Receptors: Gatekeepers of HIV-1 Infection. Curr Drug Targets Infect Disord 2 : 265 278.
32. Kazmierski W.M. Peckham J.P. Duan M. Kenakin T.P. Jenkinson S. Gudmundsson K.S. Piscitelli S.C. Feldman Paul L. ( 2005) Recent progress in the discovery of new CCR5 and CXCR4 chemokine receptor antagonists as inhibitors of HIV-1 entry. Part 2. Curr Med Chem: Anti-Infective Agents 4 : 133 152.
33. Kazmierski W. Bifulco N. Yang H. Boone L. DeAnda F. Watson C. Kenakin T. ( 2003) Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorganic Med Chem 11 : 2663 2676.
34. Peckham J. Anderson D. Aquino C. Bifulco N. Boone L. Chong P. Duan M. Ferris R. Kazmierski W. Kenakin T. Lang D. McLean E. Svolto A. Wheelan P. Youngman M. ( 2005) Design, Synthesis and Structure-activity Relationship Studies of Novel 4,4-disubstituted Piperidine Based CCR5 Antagonists as Anti-HIV-1 Agents. Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005, MEDI-059.
35. Zhang Y.-J. Moore J.P. ( 1999) Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol 73 : 3443 3448.
36. Shieh J.T.C. Albright A.V. Sharron M. Gartner S. Stritzki J. Doms R.W. Gonzalez-Scarano F. ( 1998) Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia. J Virol 72 : 4243 4249.
37. Dragic T. Litwin V. Allaway G.P. Martin S.R. Huang Y. Nagashima K.A. Cayanan C. Maddon P.J. Koup R.A. Moore J.P. Paxton W.A. ( 1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC CCR-5. Nature 381 : 667 673.
38. Alkhatib G. Combadiere C. Broder C.C. Feng Y. Kennedy P.E. Murphy P.M. Berger E.A. ( 1996) A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 : 1955 1958.
39. Feng Y. Broder C.C. Kennedy P.E. Berger E.A. ( 1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 : 872 877.
40. Connor R.I. Sheridan K.E. Ceradini D. Choe S. Landau N.R. ( 1997) Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 185 : 621 628.
41. Liu R. Paxton W.A. Choe S. Ceradini D. Martin S.R. Horuk R. MacDonald M.I. Stuhlmann H. Koup R.A. Landau N.R. ( 1996) Homozygous defect HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86 : 367 377.
42. Samson M. Libert F. Doranz B.J. Rucker J. Liesnard C. Farber C.M. Saragosti S. Lapoumerouilie C. Cognaux J. Forceille C. Muyldermans G. Verhofstede C. Collman R.G. Doms R.W. Vassart G. et al. ( 1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 : 722 725.
43. Scarlatti G. Tresoldi E. Bjorndal A. Fredricksson R. Colognesi C. Deng H.K. Malnati M.S. Piebani A. Siccardi A.G. Littman D.R. Fenyou E.M. Lusso P. ( 1997) In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Med 3 : 1259 1265.
44. Lapham C.K. Zaitseva M.B. Lee S. Romanstseva T. Golding H. ( 1999) Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nature Med 5 : 303 308.
45. Wells T.N.C. Proudfoot A.E.I. Power C.A. Marsh M. ( 1996) Chemokine receptors-the new frontier for aids research. Chem Biol 3 : 603 609.
46. Cocchi F. De Vico A.L. Garzino-Demo A. Arya S.K. Gallo R.C. Lusso P. ( 1995) Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells. Science 270 : 1811 1815.
47. Simmons G. Clapham P.R. Picard L. Offord R.E. Rosenkilde M.M. Schwartz T.W. Buser R. Wells T.N.C. Proudfoot A.E.I. ( 1997) Potential inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276 : 276 279.
48. Mack M. Luckow B. Nelson P.J. Cihak J. Simmons G. Clapham P.R. Signoret N. Marsh M. Stangassinger M. Borlat F. Wells T.N.C. Schlondorff D. Proudfoot A.E.I. ( 1998) Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 187 : 1215 1224.
49. Arenzana-Seisdedos F. Virelizier J.L. Rousset D. Clark-Lewis I. Loetscher P. Moser B. Baggiolini M. ( 1996) HIV blocked by chemokine antagonist. Nature 383 : 400 401.
50. Menten P. Struyf S. Schutyser E. Wuyts A. de Clercq E. Schols D. Proost P. Van Damme J. ( 1999) The LD78α isoform of MIP-1α is the most potent CCR5 agonist and HIV-1 inhibiting chemokine. J Clin Invest 104 : R1 R5.
51. Nishiyama Y. Murakami T. Kurita K. Yamamoto N. ( 1999) Low-molecular-weight anti-HIV-1 peptides from the amino-terminal sequence of RANTES: possible lead compounds for coreceptor-directed anti-HIV-1 compounds. Bioorg Med Chem Lett 9 : 1357 1360.
52. Garzino-Demo A. Moss R.B. Margolick J.B. Cleghorn F. Sill A. Blattner W.A. Cocchi F. Carlo D.J. DeVico A.L. Gallo R.C. ( 1999) Spontaneous and antigen-induced production of HIV-inhibitorychemokines are associated with AIDS-free status. Proc Natl Acad Sci U S A 96 : 11986 11991.
53. Trkola A. Ketas T.J. Nagashima K.A. Zhao L. Cilliers T. Morris L. Moore J.P. Maddon P.J. Olson W.C. ( 2001) Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO I40. J Virol 75 : 579 588.
54. Blanpain C.C. Doranz B.J. Vaklil J. Rucker J. Govaerts C. Baik S.S.W. Lorthoir O. Migeotte I. Libert F. Baleux F. Vassart G. Doms R.W. Parmentier M. ( 1999) Multiple charged and arpomatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein. J Biol Chem 274 : 34719 34727.
55. Blanpain C.C. Lee B. Vaklil J. Doranz B.J. Govaerts C. Migeotte Sharron M. Dupriez V. Vassart G. Doms R.W. Parmentier M. ( 1999) Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem 274 : 18902 18908.
56. Howard O.M.Z. Shirakawa A.-K. Turpin J.A. Maynard A. Tobin G.J. Carrington M. Oppenheim J.J. Dean M. ( 1999) Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 co-receptor and ligand binding function. J Biol Chem 274 : 16228 16234.
57. Tsamis F. Gavrilov S. Kajumo F. Seibert C. Kuhmann S. Ketas T. Trkola A. Palani A. Clader J.W. Tagat J.R. McCombie S. Baroudy B. Moore J.P. Sakmar T.P. Dragic T. ( 2003) Analysis of the mechanism by which the small molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type-1 entry. J Virol 77 : 5201 5208.
58. Wu L. LaRosa G. Kassam N. Gordon C.J. Heath H. Ruffing N. Chen J. Humblias J. Samson M. Parmentier M. Moore J.P. MacKay C.R. ( 1997) Interaction of the chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 186 : 1373 1381.
59. Blanpain C. Doranz B.J. Bondue A. Govaerts C. De Leener A. Vassart G. Doms R.W. Proudfoot A. Parmentier M. ( 2003) The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem 278 : 5179 5187.
60. Aramori Y. Ferguson S.S. Bieniasz P.D. Zhang J. Cullen B. Cullen M.G. ( 1997) Molecular mechanism of desensitization of the chemokine receptor CCR5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO J 16 : 4606 4616.
61. Amara A. Gall S.L. Schwartz O. Salamero J. Montes M. Loetscher P. Baggolini M. Virelizier J.L. Arenzana-Seisdedos F. ( 1997) HIV coreceptor downregulation as an antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 186 : 139 146.
62. Solari R. Offord R.E. Remy S. Aubry J.P. Wells T.N.C. Whitehorn E. Oung T. Proudfoot A.E.I. ( 1997) Receptor-mediated endocytosis of CC-chemokines. J Biol Chem 272 : 9617 9620.
63. Signoret N. Oldridge J. Pelchen-Mathews A. Klasse P.J. Tran T. Brass L.F. Rosenkilde M.M. Schwarz T.W. Holmes W. Dallas W. Luther M.A. Wells T.N. Hoxie J.A. Marsh M. ( 1997) Phorbol esters and SDF-1α induce rapid endocytosis and down-regulation of chemokine receptor CXCR4. J Cell Biol 139 : 651 664.
64. Hartley O. Gaertner H. Wilken J. Thompson D. Fish R. Ramos A. Pastore C. Dufour B. Cerini F. Melotti A. Heveker N. Picard L. Alizon M. Mosier D. Kent S. et al. ( 2004) Medicinal chemistry applied to a synthetic protein: Development of highly potent HIV entry inhibitors. Proc Natl Acad Sci U S A 101 : 16460 16465.
65. Kawamura T. Bruce S.E. Abraha A. Sugaya M. Hartley O. Offord R.E. Arts E.J. Zimmerman P.A. Blauvelt A. ( 2004) PSC-RANTES blocks human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol 78 : 7602 7609.
66. De Clercq E. ( 2005) Emerging anti-HIV drugs. Expert Opin Emerg Drugs 10 : 241 274.
67. Seibert C. Sakmar T.P. ( 2004) Small-molecule antagonists of CCR5 and CXCR4: A promising new class of anti-HIV-1 drugs. Curr Pharm Des 10 : 2041 2062.
68. Wyatt R. Sodroski J. ( 1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 : 1884 1888.
69. Poignard P. Saphire E.O. Parren P.W. Burton D.R. ( 2001) Gp120: biologic aspects of structural features. Annu Rev Immunol 19 : 253 274.
70. Trkola A. Kuhmann S.E. Strizki J.M. Maxwell E. Ketas T. Morgan T. Pugach P. Xu S. Wojcik L. Tagat J. Palani A. Shapiro S. Clader J.W. McCombie S. Reyes G.R. et al. ( 2002) HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 99 : 395 400.
71. Kuhmann S.E. Pugach P. Kunstman K.J. Taylor J. Stanfield R.L. Snyder A. Strizki J.M. Riley J. Baroudy B.M. Wilson I.A. Korber B.T. Wolinsky S.M. Moore J.P. ( 2004) Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape form small-molecule CCR inhibitor. J Virol 78 : 2790 2807.
72. Signoret N. Pelchen-Mathews A. Mack M. Proudfoot A.E. Marsh M. ( 2000) Endocytosis and recycling of the HIV coreceptor CCR5. J Cell Biol 151 : 1281 1294.
73. Signoret N. Hewlett L. Wavre S. Pelchen-Mathews A. Oppermann M. Marsh M. ( 2005) Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent. Mol Biol Cell 16 : 902 917.
74. Bohm S.K. q7 Grady E.F. Bunnett N.W. ( 1997) Regulatory mechanisms that modulate signaling by G-protein-coupled receptors. Biochem J 322 : 1 18.
75. Koenig J.A. Edwardson J.M. ( 1997) Endocytosis and recycling of G-protein-coupled receptors. Trends Pharmacol Sci 18 : 276 287.
76. Westphal R.S. Backstrom J.R. Sanders-Bush E. ( 1995) Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization. Mol Pharmacol 48 : 200 205.
77. Kovoor A. Nappey V. Kieffer B.L. Chavkin C. ( 1997) Mu and delta opioid receptors are differentially desensitized by the co-expression of β-adrenergic receptor kinase 2 and β-arrestin 2 in Xenopus oocytes. J Biol Chem 272 : 27605 27611.
78. Kenakin T.P. ( 2002) Efficacy at G protein coupled receptors. Ann Rev Pharmacol Toxicol 42 : 349 379.
79. Gong J.H. Uguccioni M. Dewald B. Baggolini M. Clark-Lewis I. ( 1996) RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem 271 : 10521 10527.
80. Atchison R.E. Gosling J. Monteclaro F.S. Franci C. Digilio L. Charo I.F. Goldsmith M. ( 1996) Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines. Science 274 : 1924 1926.
81. Farzan M. Choe H. Martin K. Marcon L. Sun Y. Sidelko M. Mackay C.R. Gerard N.P. Sodroski J. Gerard C. ( 1997) HIV-1 entry and macrophage inflammatory protein-1β-mediated signaling are independent functions of the chemokine receptor CCR5. J Biol Chem 272 : 6854 6857.
82. Gosling J. Monteclaro F.S. Atchison R.E. Arai H. Tsou C.-L. Goldsmith M.A. Charo I.F. ( 1997) Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci U S A 94 : 5061 5066.
83. Siciliano S.J. Kumann S.E. Weng Y. Madani N. Springer M.S. Lineberger J.E. Danzeisen R. Miller M.D. Kavanaugh M.P. DeMartino J.A. Kabat D. ( 1999) A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1. J Biol Chem 274 : 1905 1913.
84. Rodriguez-Frade J.M. Vila-Coro A. Martin A. Nieto M. Sanchez-Madrid F. Proudfoot A.E.I. Wells T.N.C. Martinez-A C. ( 1999) Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis. J Cell Biol 144 : 755 765.
85. Kinter A. Catanzaro A. Monaco J. Ruiz M. Justement J. Moir S. Arthos J. Oliva A. Ehler L. Mizell S. Jackson R. Ostrowski M. Hoxie J. Offord R. Fauci A.S. ( 1998) CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4+ T cells: Role of signal transduction. Proc Natl Acad Sci U S A 95 : 11880 11885.
86. Chackerian B. Long E.M. Luciw P.A. Overbaugh J. ( 1997) Human immunodeficiency virus type 1 co-receptors participate in post-entry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol 71 : 3932 3939.
87. Edinger A.L. Amedee A. Miller K. Doranz B.J. Endres M. Sharron M. Samson M. Lu Z.-H. Clements J.E. Murphey-Corb M. Peiper S.C. Parmentier M. Broder C.C. Doms R.W. ( 1997) Differential utilization of CCR5 by macrophages and T-cell tropic SIV strains. Proc Natl Acad Sci U S A 94 : 4005 4010.
88. Liu Q.-H. Williams D.A. McManus C. Baribaud F. Soms R.W. Schols D. De Clercq E. Kotlikoff M.I. Collman R.G. Freedman D. ( 2000) HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci U S A 97 : 4832 4837.
89. Berson J.F. Long D. Doranz B.J. Rucker J. Jirik F.R. Doms R.W. ( 1996) A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 70 : 6288 6295.
90. Valenzuela-Fernandez A. Palanche T. Amara A. Magerus A. Altmeyer R. Dalaunay T. Virelizier J.-L. Baleux F. Galzi J.-L. Anezana-Seisdedos F. ( 2001) Optimal inhibition of X4 HIV isolates by the CXC chemokine stromal cell-derived factor 1 requires interaction with cell surface heparan sulfate proteoglycans. J Biol Chem 276 : 26550 26558.
91. Shaheen F. Collman R.G. ( 2004) Co-receptor antagonists as HIV-1 entry inhibitors. Curr Opin Infect Dis 17 : 7 14.
92. Zhu T. Mo H. Wang N. Nam D.S. Cao Y. Koup R.A. Ho D.D. ( 1993) Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261 : 1179 1181.
93. Lee B. Sharron M. Montaner L.J. Weissman D. Doms R.W. ( 1999) Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Nat Acad Sci USA 96 : 5215 5220.
94. Verani A. q8 Lusso P. ( 2002) Chemokines as natural HIV antagonists. Curr Mol Med 2 : 691 702.
95. Schuitemaker H. Koot M. Kootstra N.A. Dercksen M.W. de Goede R.E. van Steenwijk R.P. Lange J.M. Schattenkerk J.K. Miedema F. Tersmette M. ( 1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66 : 1354 1360.
96. Lapham C.K. Zaitseva M.B. Lee S. Romanstseva T. Golding H. ( 1999) Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nat Med 5 : 303 308.
97. Buckley C.D. Amft N. Bradfield P.F. Pilling D. Ross E. Arenzana-Seisdedos F. Amara A. Curnow S.J. Lord J.M. Scheel-Toellner D. Salmon M. ( 2000) Persistent induction of the chemokine receptor CXCR4 by TGF-β1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 165 : 3423 3429.
98. Ma Q. Jones D. Springer T.A. ( 1999) The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10 : 463 471.
99. Matthys P. Hatse S. Vermeire K. Wuyts A. Bridger G. Henson G.W. De Clercq E. Billiau A. Schols D. ( 2001) AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 167 : 4686 4692.
100. Buckley C.D. Amft N. Bradfield P.F. Pilling D. Ross E. Arenzana-Seisdedos F. Amara A. Curnow S.J. Lord J.M. Scheel-Toellner D. Salmon M. ( 2000) Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 165 : 3423 3429.
101. Muller A. Homey B. Soto H. Ge N. Catron D. Buchanan M.E. McClanahan T. Murphy E. Yuan W. Wagner S.N. Barrera J.L. Mohar A. Verastegui E. Zlotnik A. ( 2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410 : 50 56.
102. Scotton C.J. Wilson J.L. Scott K. Stamp G. Wilbanks G.D. Fricker S. Bridger G. Balkwill F.R. ( 2002) Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62 : 5930 5938.
103. Yang O.O. Swanberg S.L. Lu Z. Dziejman M. McCoy J. Luster A.D. Walker B.D. Herrmann S.H. ( 1999) Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived factor 1 - beta correlates with down-modulation of CXCR4. J Virol 73 : 4582 4589.
104. Crump M.P. Gong J.H. Loetscher P. Rajarathnam K. Amara A. Arenzana-Seisdedos F. Virelizier J.L. Baggiolini M. Sykes B.D. Clark-Lewis I. ( 1997) Solution structure and basis for functional activity of stromal cell-derived factor-1, dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16 : 6996 7007.
105. Dettin M. Pasquato A. Scarinci C. Zanchetta M. De Rossi A. Di Bello C. ( 2004) Anti-HIV Activity and Conformational Studies of Peptides Derived from the C-Terminal Sequence of SDF-1. J Med Chem 47 : 3058 3064.
106. Sumner-Smith M. Zheng Y. Zhang Y.P. Twist E.M. Climie S.C. ( 1995) Antiherpetic activities of N-acetyl-nona-D-arginine amide acetate. Drugs Exp Clin Res 21 : 1 6.
107. Doranz B.J. Grovit-Ferbas K. Sharron M.P. Mao S.H. Goetz M.B. Daar E.S. Doms R.W. O'Brien W.A. ( 1997) A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 186 : 1395 1400.
108. Doranz B.J. Filion L.G. Diaz-Mitoma F. Sitar D.S. Sahai J. Baribaud F. Orsini M.J. Benovic J.L. Cameron W. Doms R.W. ( 2001) Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses 17 : 475 486.
109. Masuda M. Nakashima H. Ueda T. Naba H. Ikoma R. Otaka A. Terakawa Y. Tamamura H. Ibuka T. Murakami T. ( 1992) A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). Biochem Biophys Res Commun 189 : 845 850.
110. Tamamura H. Omagari A. Hiramatsu K. Gotoh K. Kanamoto T. Xu Y. Kodama E. Matsuoka M. Hattori T. Yamamoto N. Nakashima H. Otaka A. Fujii N. ( 2001) Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on anti-HIV peptide T140. Bioorg Med Chem Lett 11 : 1897 1902.
111. Fujii N. Nakashima H. Tamamura H. ( 2003) The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Invest Drugs 12 : 185 195.
112. Fujii N. Oishi S. Hiramatsu K. Araki T. Ueda S. Tamamura H. Otaka A. Kusano S. Terakubo S. Nakashima H. Broach J.A. Trent J.O. Wang Z. Peiper S.C. ( 2003) Molecular-size reduction of a potent CXCR4 chemokine antagonist using orthagonal combination of conformation- and sequence-based libraries. Angew Chem Int Ed 42 : 3251 3253.
113. Tamamura H. Araki T. Ueda S. Wang Z. Oishi S. Esaka A. Trent J.O. Nakashima N. Peiper S.C. Otaka A. Fujii N. ( 2005) Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem 48 : 3280 3289.
114. Tamamura H. Hiramatsu K. Ueda S. Wang Z. Kusano S. Terakubo S. Trent J.O. Peiper S.C. Yamamoto N. Nakashima H. Otaka A. Fujii N. ( 2005) Stereoselective synthesis of (L-Arg-L/D-3-(2-naphthyl)alanine)-Type (E) alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J Med Chem 48 : 380 391.
115. Ichiyama K. Yokoyama-Kumakura S. Tanaka Y. Tanaka R. Hirose K. Bannai K. Edamatsu T. Yanaka M. Niitani Y. Miyano-Kurosaki N. Takaku H. Koyanagi Y. Yamamoto N. ( 2003) A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Nat Acad Sci U S A 100 : 4185 4190.
116. Murakami T. Yoshida A. Tanaka R. Mitsuhashi S. Hirose K. Yanaka M. Yamamato N. Tanaka Y. ( 2004) KRH-2731: An Orally Bioavailable CXCR4 Antagonist is a Potent Inhibitor of HIV-1 Infection. 11th Conference on Retroviruses and Opportunistic Infections February 8-11, 2004, San Francisco, CA, Abstract no. 541.
117. Yamazaki T. Saitou A. Ono M. Yokoyama S. Bannai K. Hirose K. Yanaka M. ( 2003) Preparation of Amino Acid Amide Derivatives as Antagonists of Chemokine CXCR4 Receptor. WO 029218.
118. Yamazaki T. q10 Kikumoto S. Ono M. Saitou A. Takahashi H. Kumakura S. Hirose K. ( 2004) Preparation of Bis(heterocyclylmethyl)amine Compounds as Chemokine Receptor CXCR4 antagonists. WO 024697.
119. De Clercq E. ( 2003) The bicyclam AMD3100 story. Nat Rev Drug Discov 2 : 581 587.
120. Bridger G. Skerlj R. Kaller A. Harwig C. Bogucki D. Wilson T.R. Crawford J. McEachern E.J. Atsma B. Nan S. Zhou Y. Schols D. Smith C.D. Di Fluri R.M. ( 2002) Chemokine Receptor Binding Heterocyclic Compounds. WO22600.
121. Bridger G. Skerlj R. Kaller A. Harwig C. Bogucki D. Wilson T.R. Crawford J. McEachern E.J. Atsma B. Nan S. Zhou Y. Schols D. Smith C.D. Di Fluri R.M. ( 2002) Chemokine Receptor-binding Heterocyclic Compounds, Particularly (5,6,7,8-tetrahydroquinolin-8-yl)Amino- and (1H-benzimidazol-2-yl)methyl- containing Aromatic and Heteroaromatic Amides, Useful for Treating Infection with HIV and FIV. WO22599.
122. Bridger G. Skerlj R. Kaller A. Harwig C. Bogucki D. Wilson T.R. Crawford J. McEachern E.J. Atsma B. Nan S. Zhou Y. Schols D. Smith C.D. Di Fluri R.M. ( 2002) Chemokine Receptor Binding Heterocyclic Compounds. WO34745.
123. Bridger G. Skerlj R. Kaller A. Harwig C. Bogucki D. Wilson T.R. Crawford J. McEachern E.J. Atsma B. Nan S. Zhou Y.S.D. Smith C.D. Di Fluri R.M. ( 2003) Preparation of Chemokine Receptor Binding (benzimidazol-2-ylmethyl)(5,6,7,8- tetrahydroquinolin-8-yl)Amines and Related Heterocyclic Compounds with Enhanced Efficacy Against AIDS and Other Disorders. WO 055876.
124. Bridger G. Skerlj R. Kaller A. Harwig C. Bogucki D. Wilson T.R. Crawford J. McEachern E.J. Atsma B. Nan S. Zhou Y.S.D. Smith C.D. Di Fluri R.M. ( 2004) Preparation of Chemokine Receptor Binding (benzimidazol-2-ylmethyl)(5,6,7,8- tetrahydroquinolin-8-yl)Amines and Related Heterocyclic Compounds with Enhanced Efficacy Against AIDS and Other Disorders. US 019058.
125. Hruby V.J. Al-Obeidi F. Kazmierski W. ( 1990) Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. Biochem J 268 : 249 262.
126. Hruby V.J. Li G. Haskell-Luevano C. Shenderovich M. ( 1997) Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers 43 : 219 266.
127. Al-Obeidi F. Hruby V.J. Sawyer T.K. ( 1998) Peptide and peptidomimetic libraries. Mol Biotechnol 9 : 205 223.